(Q37293135)

19 August 2017

1 reference

title

Vascular complications of selected cancer therapies (English)

1 reference

19 August 2017

Iyad N Daher

1

1 reference

19 August 2017

Edward T H Yeh

series ordinal

2

1 reference

19 August 2017

publication date

14 October 2008

1 reference

Nature Clinical Practice Cardiovascular Medicine

19 August 2017

published in

1 reference

19 August 2017

volume

5

1 reference

19 August 2017

issue

12

1 reference

19 August 2017

page(s)

797-805

1 reference

Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Cardiotoxicity induced by chemotherapy and antibody therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Risk of cardiac death after adjuvant radiotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

5-Fluorouracil cardiotoxicity: a critical review

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Cardiac toxicity of 5-fluorouracil: a study on 1083 patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Vascular toxicity associated with antineoplastic agents

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Upper extremity deep venous thrombosis in patients with 5-fluorouracil-containing adjuvant chemotherapy--three case reports and a review

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

5-Fluorouracil-induced Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Cardiotoxicity of 5-fluorouracil.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Training enhances vascular relaxation after chemotherapy-induced vasoconstriction

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

The anti-neoplastic drug 5-fluorouracil produces echinocytosis and affects blood rheology

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

The influence of 5-fluorouracil and methotrexate on vascular endothelium. An experimental study using endothelial cells in the culture

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Targeted therapy of colorectal cancer: clinical experience with bevacizumab

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Managing patients treated with bevacizumab combination therapy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab?

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Genentech discloses safety concerns over Avastin

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Bevacizumab in metastatic colorectal cancer: a left intracardiac thrombotic event

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Chemotherapy with bevacizumab, irinotecan, 5-fluorouracil and leucovorin (IFL) associated with a large, embolizing thrombus in the thoracic aorta

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Autocrine VEGF signaling is required for vascular homeostasis

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Mechanisms of adverse effects of anti-VEGF therapy for cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Sunitinib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Sorafenib for the treatment of advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Acute Coronary Events Following Cisplatin-Based Chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Cardiovascular morbidity in long-term survivors of metastatic testicular cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Thalidomide as initial therapy for early-stage myeloma

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Systematic review to establish the safety profiles for direct and indirect inhibitors of p38 Mitogen-activated protein kinases for treatment of cancer. A systematic review of the literature

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Arterial thrombosis and thalidomide

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Thalidomide: a new anticancer drug?

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Lenalidomide in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1375

7 January 2021

Identifiers

DOI

10.1038/NCPCARDIO1375

1 reference

19 August 2017

1 reference